Ash Biotech

Ash Biotech is focused on enabling enhanced understanding and more informed decision-making in determining the efficacy and safety of potential new drugs; and on finding new uses for "old" or "failed" drugs, through the use of its proprietary "phenotype-based" drug discovery technologies. The company was founded by European Biotech industry leaders who have pioneered: ultra high-throughput screening of small-molecule drugs; high-throughput screening of antibody drugs; and who played important roles in the establishment of antibody drugs as the world's most important new class of drugs. The founders have played key roles in growing biotech/pharma companies in Europe and the US to a combined exit values of over two and a half billion dollars. The company is privately held, and is located in Cambridge UK. The has been developing its platform technology for the last four years, and will be revealing details of its technology, and its initial product offering, during the first quarter of 2010. If you would like us to let you know when we release more details, please send an email to news@ashbiotech.com and we'll keep you informed.